<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980980</url>
  </required_header>
  <id_info>
    <org_study_id>PH000223K</org_study_id>
    <secondary_id>HHSA2902005003I</secondary_id>
    <secondary_id>TO #11</secondary_id>
    <nct_id>NCT00980980</nct_id>
  </id_info>
  <brief_title>Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)</brief_title>
  <acronym>REDUCE-MRSA</acronym>
  <official_title>Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard Pilgrim Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Corporation of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Population Medicine, Harvard Medical School / Harvard Pilgrim Healthcare Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard Pilgrim Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Randomized Evaluation of Decolonization versus Universal Clearance to Eliminate MRSA
      (REDUCE MRSA) Trial is a cluster randomized trial of the comparative effectiveness of three
      strategies to prevent methicillin-resistant Staphylococcus aureus (MRSA) in intensive care
      units. The three strategies to be evaluated are:

        -  screening on admission followed by isolation of MRSA+ patients

        -  screening on admission followed by isolation and decolonization of MRSA+ patients

        -  universal decolonization on admission with no screening. The decolonization regimen
           involves bathing with chlorhexidine plus intra-nasal application of mupirocin. The main
           outcome will be MRSA+ clinical cultures.

      The study is a partnership between the CDC, the CDC Prevention Epicenters, and the Hospital
      Corporation of America.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline data involving 12 months of data for participating hospitals (July 2008 - June 2009)
      was collected prior to randomization to account for size and ICU baseline prevalence of MRSA
      in randomization scheme. Randomization occurred at the hospital level.

      Eligibility survey was conducted to determine exclusion criteria.

      As of May 2010, enrollment has been closed. 45 hospitals were randomized, but two were found
      to meet exclusion criteria and were excluded. As-randomized (or as-assigned) analysis
      included 43 hospitals, representing 74 ICUs. Individual (patient-level) subject enrollment
      during intervention is 74,256.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Main Outcome: Patients With Nosocomial MRSA Clinical Cultures</measure>
    <time_frame>The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.</time_frame>
    <description>Hazard ratio for ICU-attributable MRSA+ clinical cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRSA Bloodstream Infection</measure>
    <time_frame>The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.</time_frame>
    <description>Hazard ratio for ICU-attributable MRSA+ blood cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-attributable All-pathogen Bloodstream Infection</measure>
    <time_frame>The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.</time_frame>
    <description>Hazard ratio for ICU-attributable positive blood culture from any pathogen, comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Impact on Healthcare Costs</measure>
    <time_frame>12-month period</time_frame>
    <description>Costs (in dollars) per 1000 ICU-admissions associated with 3 ICU strategies to reduce ICU Bloodstream infection (BSI), (Arms 1-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Culture Contamination Rates</measure>
    <time_frame>24-month time frame for this analysis represents a 6-month baseline and 18-month intervention period.</time_frame>
    <description>Odds ratio for ICU-attributable blood culture contamination rates, comparing Baseline to Intervention period across Arms, accounting for clustering by hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Impact on Bacteriuria and Candiduria</measure>
    <time_frame>30-month time frame represents 12-month baseline and 18-month intervention periods.</time_frame>
    <description>Proportional hazard ratio for as-randomized, unadjusted, ICU-attributable bacteriuria, comparing Baseline to Intervention period across Arms, accounting for clustering by hospital. High-level bacteriuria is defined as ≥50,000 CFU/mL, high-level candiduria is defined as ≥50,000 CFU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Impact on Mupirocin Susceptibility of MRSA Isolates</measure>
    <time_frame>25-month time frame represents 7-month baseline and 18-month intervention periods</time_frame>
    <description>Odds ratio for MRSA+ isolates from ICU patients expressing low-level mupirocin resistance (LLMR) and high-level mupirocin resistance (HLMR), comparing baseline to intervention period across arms, accounting for clustering by hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Impact on Chlorhexidine Susceptibility of MRSA Isolates</measure>
    <time_frame>25-month time frame represents 7-month baseline and 18-month intervention periods</time_frame>
    <description>Frequency of MRSA+ isolates from ICU patients with reduced susceptibility to chlorhexidine (CHG) (MIC &gt;4 μg/ml), comparing baseline to intervention period across arms, accounting for clustering by hospital.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74256</enrollment>
  <condition>Methicillin-resistant Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>Arm 1: Usual Care-Active Surveillance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Targeted Decolonization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Universal Decolonization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine bath and nasal mupirocin</intervention_name>
    <description>The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
    <arm_group_label>Arm 2: Targeted Decolonization</arm_group_label>
    <arm_group_label>Arm 3: Universal Decolonization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria will include all HCA hospitals that reside in US states where
             physicians do NOT routinely prescribe decolonization for MRSA + ICU patients.

        Exclusion Criteria:

          -  Exclusion criteria will include hospitals where ICU physicians often prescribe
             decolonization for MRSA+ ICU patients.

          -  Dedicated burn ICUs will also be excluded due to the inability to perform routine
             bathing.

          -  Finally, since the intent is to assess the intervention in adult ICUs, pediatric
             hospitals will be excluded although patients &lt;13 years old that are admitted to
             participating adult ICUs will be included in the unit-based intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Platt, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Population Medicine, Harvard Medical School / Harvard Pilgrim Healthcare Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Septimus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Corporation of America (HCA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Huang, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alaska Regional</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Robles Hosp &amp; Med Ctr</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Center of Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blake Medical Center</name>
      <address>
        <city>Brandenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandon Hospital</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Hosp Corp S Broward (Westside)</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palms West Hospital</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plantation General</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Med Cr Bayonet Point</name>
      <address>
        <city>Hudson</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Largo Medical Center</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Park Med Ctr</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fawcett Memorial Hospital</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital of Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bay Hospital</name>
      <address>
        <city>Sun City Center</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Regional Med Ctr</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coliseum (Macon) Northside</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coliseum Medical Center</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cartersville Medical Center</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Idaho Reg Med Ctr</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Garden Park Medical Center</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee's Summit Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overland Park Regional Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Belton Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moutainview Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkland Medical Center</name>
      <address>
        <city>Derry</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Strand Regional Medical Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkridge Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stonecrest</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. David's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del Sol Medical Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Palmas Medical Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clear Lake Regional</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montgomery Regional Hospital</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Alleghany Regional Hospital</name>
      <address>
        <city>LowMoor</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulaski Community Hospital</name>
      <address>
        <city>Pulaski</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chippenham Johnston Willis</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nejm.org/doi/full/10.1056/NEJMoa1207290</url>
    <description>NEJM Study Results Publication</description>
  </link>
  <link>
    <url>http://www.ahrq.gov/professionals/systems/hospital/universal_icu_decolonization/index.html</url>
    <description>AHRQ Toolkit: Universal ICU Decolonization: An Enhanced Protocol</description>
  </link>
  <reference>
    <citation>Platt R, Takvorian SU, Septimus E, Hickok J, Moody J, Perlin J, Jernigan JA, Kleinman K, Huang SS. Cluster randomized trials in comparative effectiveness research: randomizing hospitals to test methods for prevention of healthcare-associated infections. Med Care. 2010 Jun;48(6 Suppl):S52-7. doi: 10.1097/MLR.0b013e3181dbebcf.</citation>
    <PMID>20473200</PMID>
  </reference>
  <reference>
    <citation>Huang SS, Septimus E, Platt R. Targeted decolonization to prevent ICU infections. N Engl J Med. 2013 Oct 10;369(15):1470-1. doi: 10.1056/NEJMc1309704.</citation>
    <PMID>24106942</PMID>
  </reference>
  <results_reference>
    <citation>Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra L, Hartford F, Hayden MK, Jernigan JA, Weinstein RA, Fraser VJ, Haffenreffer K, Cui E, Kaganov RE, Lolans K, Perlin JB, Platt R; CDC Prevention Epicenters Program; AHRQ DECIDE Network and Healthcare-Associated Infections Program. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013 Jun 13;368(24):2255-65. doi: 10.1056/NEJMoa1207290. Epub 2013 May 29. Erratum in: N Engl J Med. 2013 Aug 8;369(6):587. N Engl J Med. 2014 Feb 27;370(9):886.</citation>
    <PMID>23718152</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2009</study_first_submitted>
  <study_first_submitted_qc>September 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <results_first_submitted>May 14, 2014</results_first_submitted>
  <results_first_submitted_qc>June 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2014</results_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harvard Pilgrim Health Care</investigator_affiliation>
    <investigator_full_name>Richard Platt</investigator_full_name>
    <investigator_title>Professor and Department Chair</investigator_title>
  </responsible_party>
  <keyword>MRSA infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>45 out of 165 Hospital Corporation of America (HCA) hospitals were recruited for this trial of adult ICUs. There was a 12-month baseline period from January 1 through December 31, 2009; a phase-in period from January 1 through April 7, 2010; and an 18-month intervention period from April 8, 2010 through September 30, 2011.</recruitment_details>
      <pre_assignment_details>74,256 patients were involved in the intervention period among adult ICUs from the 43 participating hospitals. Routinely collected information for about 48,390 individuals cared for during the baseline period was used for comparison to the experience of the patients in all three arms of the Intervention period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Usual Care-Active Surveillance</title>
          <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Targeted Decolonization</title>
          <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of baths with 2% chlorhexidine cloths plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Universal Decolonization</title>
          <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance , Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Hospital</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>'Number of Participant' totals reflect total Baseline and Intervention participants combined. 45 hospitals were randomized to a study group, 2 dropped due to exclusion criteria, 43 began the assigned intervention. 1 hospital withdrew during the intervention and was included in as-assigned analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Usual Care-Active Surveillance</title>
          <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Targeted Decolonization</title>
          <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: Universal Decolonization</title>
          <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39296"/>
            <count group_id="B2" value="39970"/>
            <count group_id="B3" value="43380"/>
            <count group_id="B4" value="122646"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Baseline Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="52" upper_limit="77"/>
                    <measurement group_id="B2" value="66" lower_limit="53" upper_limit="77"/>
                    <measurement group_id="B3" value="65" lower_limit="51" upper_limit="77"/>
                    <measurement group_id="B4" value="65" lower_limit="52" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intervention Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="52" upper_limit="77"/>
                    <measurement group_id="B2" value="66" lower_limit="53" upper_limit="77"/>
                    <measurement group_id="B3" value="65" lower_limit="52" upper_limit="77"/>
                    <measurement group_id="B4" value="65" lower_limit="52" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>Proportion of female study participants, during baseline and intervention study phases.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Females - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7465"/>
                    <measurement group_id="B2" value="7183"/>
                    <measurement group_id="B3" value="8314"/>
                    <measurement group_id="B4" value="22962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Males - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8351"/>
                    <measurement group_id="B2" value="8035"/>
                    <measurement group_id="B3" value="9042"/>
                    <measurement group_id="B4" value="25428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Females - Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11176"/>
                    <measurement group_id="B2" value="11683"/>
                    <measurement group_id="B3" value="12361"/>
                    <measurement group_id="B4" value="35220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Males - Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12304"/>
                    <measurement group_id="B2" value="13069"/>
                    <measurement group_id="B3" value="13663"/>
                    <measurement group_id="B4" value="39036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Overall Number of Participants, by Phase</title>
          <description>This table reflects number of admissions with an ICU stay during the Baseline and Intervention periods, separately. Please note that the table above, &quot;Overall Number of Baseline Participants&quot; reflects the total number of participants for which baseline characteristics were measured, across Baseline and Intervention phases combined.</description>
          <units>Admissions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Baseline Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15816"/>
                    <measurement group_id="B2" value="15218"/>
                    <measurement group_id="B3" value="17356"/>
                    <measurement group_id="B4" value="48390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intervention Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23480"/>
                    <measurement group_id="B2" value="24752"/>
                    <measurement group_id="B3" value="26024"/>
                    <measurement group_id="B4" value="74256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Main Outcome: Patients With Nosocomial MRSA Clinical Cultures</title>
        <description>Hazard ratio for ICU-attributable MRSA+ clinical cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
        <time_frame>The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.</time_frame>
        <population>The total number of participants analyzed included the table reflects the combined total of baseline and intervention participants, for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care-Active Surveillance</title>
            <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Targeted Decolonization</title>
            <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Universal Decolonization</title>
            <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance , Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Main Outcome: Patients With Nosocomial MRSA Clinical Cultures</title>
          <description>Hazard ratio for ICU-attributable MRSA+ clinical cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
          <population>The total number of participants analyzed included the table reflects the combined total of baseline and intervention participants, for each arm.</population>
          <units>hazard ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39296"/>
                <count group_id="O2" value="39970"/>
                <count group_id="O3" value="43380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.77" upper_limit="1.10"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.63" upper_limit="0.89"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.52" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Proportional-hazards models</method>
            <method_desc>Proportional-hazards models with shared frailties accounted for clustering within hospitals.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRSA Bloodstream Infection</title>
        <description>Hazard ratio for ICU-attributable MRSA+ blood cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
        <time_frame>The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.</time_frame>
        <population>The total number of participants analyzed included the table reflects the combined total of baseline and intervention participants, for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care-Active Surveillance</title>
            <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Targeted Decolonization</title>
            <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Universal Decolonization</title>
            <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>MRSA Bloodstream Infection</title>
          <description>Hazard ratio for ICU-attributable MRSA+ blood cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
          <population>The total number of participants analyzed included the table reflects the combined total of baseline and intervention participants, for each arm.</population>
          <units>hazard ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39296"/>
                <count group_id="O2" value="39970"/>
                <count group_id="O3" value="43380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.82" upper_limit="1.85"/>
                    <measurement group_id="O2" value="1.23" lower_limit="0.80" upper_limit="1.90"/>
                    <measurement group_id="O3" value="0.72" lower_limit="0.48" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU-attributable All-pathogen Bloodstream Infection</title>
        <description>Hazard ratio for ICU-attributable positive blood culture from any pathogen, comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
        <time_frame>The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.</time_frame>
        <population>The total number of participants analyzed included the table reflects the combined total of baseline and intervention participants, for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care-Active Surveillance</title>
            <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Targeted Decolonization</title>
            <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Universal Decolonization</title>
            <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>ICU-attributable All-pathogen Bloodstream Infection</title>
          <description>Hazard ratio for ICU-attributable positive blood culture from any pathogen, comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.</description>
          <population>The total number of participants analyzed included the table reflects the combined total of baseline and intervention participants, for each arm.</population>
          <units>Hazard ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39296"/>
                <count group_id="O2" value="39970"/>
                <count group_id="O3" value="43380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.84" upper_limit="1.16"/>
                    <measurement group_id="O2" value="0.78" lower_limit="0.66" upper_limit="0.91"/>
                    <measurement group_id="O3" value="0.56" lower_limit="0.49" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intervention Impact on Healthcare Costs</title>
        <description>Costs (in dollars) per 1000 ICU-admissions associated with 3 ICU strategies to reduce ICU Bloodstream infection (BSI), (Arms 1-3).</description>
        <time_frame>12-month period</time_frame>
        <population>Annual adult ICU admissions per hospital, over the course of 1 year.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care-Active Surveillance</title>
            <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Targeted Decolonization</title>
            <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Universal Decolonization</title>
            <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Intervention Impact on Healthcare Costs</title>
          <description>Costs (in dollars) per 1000 ICU-admissions associated with 3 ICU strategies to reduce ICU Bloodstream infection (BSI), (Arms 1-3).</description>
          <population>Annual adult ICU admissions per hospital, over the course of 1 year.</population>
          <units>Dollars per 1000 ICU-admissions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="1000"/>
                <count group_id="O3" value="1000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cost of MRSA screening tests</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9,120"/>
                    <measurement group_id="O2" value="9,120"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cost of contact precautions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69,010"/>
                    <measurement group_id="O2" value="68,830"/>
                    <measurement group_id="O3" value="24,890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cost of decolonization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4,679"/>
                    <measurement group_id="O3" value="36,500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU costs (not including intervention costs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19,320,000"/>
                    <measurement group_id="O2" value="19,250,000"/>
                    <measurement group_id="O3" value="19,170,000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Culture Contamination Rates</title>
        <description>Odds ratio for ICU-attributable blood culture contamination rates, comparing Baseline to Intervention period across Arms, accounting for clustering by hospital.</description>
        <time_frame>24-month time frame for this analysis represents a 6-month baseline and 18-month intervention period.</time_frame>
        <population>The number of participants analyzed reflects the combined total of baseline and intervention admissions, with an ICU stay and a blood draw set, for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care-Active Surveillance</title>
            <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Targeted Decolonization</title>
            <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Universal Decolonization</title>
            <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Culture Contamination Rates</title>
          <description>Odds ratio for ICU-attributable blood culture contamination rates, comparing Baseline to Intervention period across Arms, accounting for clustering by hospital.</description>
          <population>The number of participants analyzed reflects the combined total of baseline and intervention admissions, with an ICU stay and a blood draw set, for each arm.</population>
          <units>Odds Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4154"/>
                <count group_id="O2" value="4141"/>
                <count group_id="O3" value="4982"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>As randomized, unadjusted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.58" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.72" upper_limit="1.23"/>
                    <measurement group_id="O3" value="0.56" lower_limit="0.44" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>As randomized, adjusted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.57" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.7" upper_limit="1.22"/>
                    <measurement group_id="O3" value="0.55" lower_limit="0.43" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intervention Impact on Bacteriuria and Candiduria</title>
        <description>Proportional hazard ratio for as-randomized, unadjusted, ICU-attributable bacteriuria, comparing Baseline to Intervention period across Arms, accounting for clustering by hospital. High-level bacteriuria is defined as ≥50,000 CFU/mL, high-level candiduria is defined as ≥50,000 CFU/mL.</description>
        <time_frame>30-month time frame represents 12-month baseline and 18-month intervention periods.</time_frame>
        <population>The number of participants analyzed reflects the combined total of baseline and intervention admissions with an ICU stay, for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care-Active Surveillance</title>
            <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Targeted Decolonization</title>
            <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Universal Decolonization</title>
            <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Intervention Impact on Bacteriuria and Candiduria</title>
          <description>Proportional hazard ratio for as-randomized, unadjusted, ICU-attributable bacteriuria, comparing Baseline to Intervention period across Arms, accounting for clustering by hospital. High-level bacteriuria is defined as ≥50,000 CFU/mL, high-level candiduria is defined as ≥50,000 CFU/mL.</description>
          <population>The number of participants analyzed reflects the combined total of baseline and intervention admissions with an ICU stay, for each arm.</population>
          <units>Hazard Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39296"/>
                <count group_id="O2" value="39970"/>
                <count group_id="O3" value="43380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High-level bacteriuria (all patients)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.88" upper_limit="1.18"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.76" upper_limit="1.02"/>
                    <measurement group_id="O3" value="0.87" lower_limit="0.77" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-level bacteriuria (women)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.80" upper_limit="1.17"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.70" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.79" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-level bacteriuria (men)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.85" upper_limit="1.40"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.79" upper_limit="1.29"/>
                    <measurement group_id="O3" value=".78" lower_limit=".63" upper_limit=".98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-level candiduria (all patients)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit=".95" upper_limit="1.37"/>
                    <measurement group_id="O2" value=".99" lower_limit=".83" upper_limit="1.18"/>
                    <measurement group_id="O3" value=".83" lower_limit=".70" upper_limit=".99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-level candiduria (women)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit=".88" upper_limit="1.36"/>
                    <measurement group_id="O2" value="1.00" lower_limit=".81" upper_limit="1.24"/>
                    <measurement group_id="O3" value=".94" lower_limit=".76" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-level candiduria (men)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit=".88" upper_limit="1.68"/>
                    <measurement group_id="O2" value="1.01" lower_limit=".73" upper_limit="1.39"/>
                    <measurement group_id="O3" value=".63" lower_limit=".45" upper_limit=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bacteriuria (all patients)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".95" lower_limit=".84" upper_limit="1.09"/>
                    <measurement group_id="O2" value=".92" lower_limit=".8" upper_limit="1.04"/>
                    <measurement group_id="O3" value=".86" lower_limit=".77" upper_limit=".97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bacteriuria (women)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".91" lower_limit=".77" upper_limit="1.08"/>
                    <measurement group_id="O2" value=".86" lower_limit=".73" upper_limit="1.01"/>
                    <measurement group_id="O3" value=".95" lower_limit=".82" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bacteriuria (men)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit=".81" upper_limit="1.25"/>
                    <measurement group_id="O2" value="1.04" lower_limit=".83" upper_limit="1.3"/>
                    <measurement group_id="O3" value=".74" lower_limit="0.61" upper_limit=".9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intervention Impact on Mupirocin Susceptibility of MRSA Isolates</title>
        <description>Odds ratio for MRSA+ isolates from ICU patients expressing low-level mupirocin resistance (LLMR) and high-level mupirocin resistance (HLMR), comparing baseline to intervention period across arms, accounting for clustering by hospital.</description>
        <time_frame>25-month time frame represents 7-month baseline and 18-month intervention periods</time_frame>
        <population>The total number of participants analyzed reflects the combined total of baseline and intervention participants during the outcome time frame, for each arm. The total number of units analyzed reflects the combined total of MRSA+ isolates collected from ICU patients during baseline and intervention phase, for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care-Active Surveillance</title>
            <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Targeted Decolonization</title>
            <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Universal Decolonization</title>
            <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Intervention Impact on Mupirocin Susceptibility of MRSA Isolates</title>
          <description>Odds ratio for MRSA+ isolates from ICU patients expressing low-level mupirocin resistance (LLMR) and high-level mupirocin resistance (HLMR), comparing baseline to intervention period across arms, accounting for clustering by hospital.</description>
          <population>The total number of participants analyzed reflects the combined total of baseline and intervention participants during the outcome time frame, for each arm. The total number of units analyzed reflects the combined total of MRSA+ isolates collected from ICU patients during baseline and intervention phase, for each arm.</population>
          <units>Odds Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>MRSA+ isolates</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29643"/>
                <count group_id="O2" value="28297"/>
                <count group_id="O3" value="32601"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>MRSA+ isolates</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1303"/>
                <count group_id="O2" value="1460"/>
                <count group_id="O3" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical MRSA: LLMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.22" upper_limit="4.85"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.34" upper_limit="6.14"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.1" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical MRSA: HLMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.11" upper_limit="5.68"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.15" upper_limit="5.44"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.16" upper_limit="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU-attributable MRSA: LLMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.37" upper_limit="7.55"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.01" upper_limit="99"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.10" upper_limit="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU-attributable MRSA: HLMR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.25" upper_limit="9.02"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.09" upper_limit="5.06"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.134" upper_limit="15.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intervention Impact on Chlorhexidine Susceptibility of MRSA Isolates</title>
        <description>Frequency of MRSA+ isolates from ICU patients with reduced susceptibility to chlorhexidine (CHG) (MIC &gt;4 μg/ml), comparing baseline to intervention period across arms, accounting for clustering by hospital.</description>
        <time_frame>25-month time frame represents 7-month baseline and 18-month intervention periods</time_frame>
        <population>The total number of participants analyzed reflects the combined total of baseline and intervention participants during the outcome time frame, for each arm. The total number of units analyzed reflects the combined total of MRSA+ isolates collected from ICU patients during baseline and intervention phase, for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care-Active Surveillance</title>
            <description>Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Targeted Decolonization</title>
            <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Universal Decolonization</title>
            <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Intervention Impact on Chlorhexidine Susceptibility of MRSA Isolates</title>
          <description>Frequency of MRSA+ isolates from ICU patients with reduced susceptibility to chlorhexidine (CHG) (MIC &gt;4 μg/ml), comparing baseline to intervention period across arms, accounting for clustering by hospital.</description>
          <population>The total number of participants analyzed reflects the combined total of baseline and intervention participants during the outcome time frame, for each arm. The total number of units analyzed reflects the combined total of MRSA+ isolates collected from ICU patients during baseline and intervention phase, for each arm.</population>
          <units>MRSA isolates non-susceptible to CHG</units>
          <param>Number</param>
          <units_analyzed>MRSA+ isolates</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29643"/>
                <count group_id="O2" value="28297"/>
                <count group_id="O3" value="32601"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>MRSA+ isolates</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1303"/>
                <count group_id="O2" value="1460"/>
                <count group_id="O3" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>Adverse event monitoring and reporting occurred during intervention only, as decolonizing agents were not used during the baseline period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Usual Care-Active Surveillance</title>
          <description>Active Surveillance in All Adult ICUs Contact Precautions for MRSA+</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Targeted Decolonization</title>
          <description>Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths, plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Universal Decolonization</title>
          <description>Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance , Contact Precautions for MRSA+
Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24752"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26024"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23480"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24752"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mild</sub_title>
                <description>A mild adverse event included any criteria less than moderate</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24752"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="26024"/>
              </event>
              <event>
                <sub_title>Moderate</sub_title>
                <description>A moderate adverse event included any moderate erythema, scaling or blistering that involves &gt;30% body surface area</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24752"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26024"/>
              </event>
              <event>
                <sub_title>Severe</sub_title>
                <description>A severe adverse event included any severe erythema, scaling or blistering that involves &gt;30% body surface area</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24752"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26024"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Susan Huang</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>949-824-5073</phone>
      <email>sshuang@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

